NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
Quantum BioPharma's Drug Candidate and Growth Strategy: FAQ
Quantum BioPharma executive co-chairman Anthony Durkacz discussed the company's MS drug candidate Lucid-MS and its alcohol metabolism accelerator unbuzzd on a podcast, highlighting the company's strategy and recent developments.
The podcast focused on Quantum BioPharma's lead MS drug candidate Lucid-MS, its growth strategy, and an update on unbuzzd, an alcohol metabolism accelerator.
Anthony Durkacz, the executive co-chairman and co-founder of Quantum BioPharma, appeared as a guest.
Lucid-MS is Quantum BioPharma's lead drug candidate for treating multiple sclerosis.
Unbuzzd is an innovative, clinically validated alcohol metabolism accelerator designed to help people sober up faster.
It allows leaders to explain complex technologies, discuss development strategies, and provide context that is difficult to capture in traditional press releases.
The article was published on July 1, 2026, indicating the podcast was released around that time.
More information is available in the company's newsroom at https://ibn.fm/QNTM and through the InvestorBrandNetwork website.
Forward-looking statements involve risks and uncertainties, including those detailed in the company's SEC filings, and actual results may differ materially.